Zhongshan Innovision

Innovision Biopharmaceuticals is a clinical-stage biotechnology company dedicated to developing innovative therapies for vision-threatening ophthalmic diseases. Headquartered in Zhongshan, China, the company focuses on high-prevalence conditions such as diabetic macular edema, age-related macular degeneration, and glaucoma. Its lead candidate, IVN301, is a bispecific antibody targeting both VEGF and Ang-2, designed to provide superior efficacy and durability compared to current standard-of-care monotherapies. Innovision leverages a proprietary protein engineering platform and advanced drug delivery technologies to create a robust pipeline of biologics and small molecules. The company is led by an experienced management team with a track record of successful drug development in both China and the United States.